Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Advancing Lymphoma Diagnosis and Treatment TOGETHER: the CALYM Carnot Institute Organizes its 3rd Scientific and Partnering Day

Posted on: 21 Sep 16

On 17 October 2016 in Paris, the CALYM Carnot Institute, international academic research and development leader in the lymphoma field, will organize its third scientific and partnering day for its industrial partners. This international event will take place as part of CALYM's new structure following its recent “Carnot institute” accreditation by the French Government.

The 3rd CALYM Scientific and Partnering Day offers pharmaceutical, biotech, diagnostics and imaging companies a unique opportunity to meet international lymphoma experts and discuss with them R&D partnering needs. The new lymphoma R&D offering and latest research results of CALYM researchers and clinicians will be presented, from the identification of new therapeutic targets to Phase III pivotal clinical trials and beyond. This event is the first of its kind since the new "Carnot 3" structure was established.

French Government ensures long-term sustainability of CALYM

On 6 July, CALYM received "Carnot 3 institute" accreditation in its new scope: the LYSA ( and LYSARC associations and 13 leading public research laboratories in the lymphoma field.
CALYM is one of the 29 French research institutes to be granted accreditation, out of 45 applications received. They will benefit from the contribution of their partnering research revenues via the National Research Agency, up to a stable budgetary amount of €57 M in 2016. "This is an important new step for the institute, which will have a significant impact towards making progress in lymphoma research. Our scientific and partnering day is an opportunity for us to demonstrate our know-how in this field" stated Pascal Deschaseaux, CEO of CALYM.

One of CALYM's major challenges over the period is to foster the preclinical/clinical research continuum with regard to lymphoma therapies and diagnostics notably via its projects of preclinical development centers, its translational research and its early-phase clinical trials platform.

These scientific and medical challenges are in line with the interests of established industrial partners or new ones that CALYM identifies in France, via FINDMED ( and abroad, via GLOBAL CARE Initiative (, two consortiums of Carnot institutes, to which CALYM belongs.

For more information about the 3 rd CALYM scientific and partnering day:,581.html
Free but compulsory registration via before 30 September.

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.

View source version on

Business Wire

Last updated on: 21/09/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.